Chronic Myeloid Leukemia Clinical Trials

Birmingham : University of Alabama Comprehensive Cancer Center University of Alabama

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Muscle Shoals : Northwest Alabama Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Sedona : Arizona Oncology Associates, PC - NAHOA

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Tucson : Arizona Oncology Associates, PC - HOPE

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Hot Springs : Genesis Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Jonesboro : NEA Baptist Clinic

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Little Rock : Little Rock Hematology Oncology Associates

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Duarte : City of Hope Updated

A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

View More »

Anaheim : Pacific Cancer Medical Center, Inc

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Burbank : US Oncology - Providence Health System, Site #167

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Escondido : Southwest Cancer Care Medical Group

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Glendora : Wilshire Oncology Medical Group, Inc

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

La Jolla : Moores UCSD Cancer Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Los Angeles : UCLA Department of Medicine, Site #027

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Los Angeles : University of Southern California

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Orange : Children's Hospital of Orange County CHOC

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Oxnard : PMK Medical Group, Inc. DBA Ventura

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Palo Alto : Stanford University Medical Center Oncology

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Pleasant Hill : Bay Area Cancer Research Group, Site #157

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Pleasant Hill : Bay Area Cancer Research Group, Site #156

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

San Francisco : University of California Medical Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Boulder : Rocky Mountain Cancer Centers, Site #191

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Boulder : Rocky Mountain Cancer Centers

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Manchester : Medical Oncology and Blood Disorders, LLP

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Southington : Cancer Center of Central Connecticut, Site #147

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Newark : Christiana Care Health Services, Site #155

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Boynton Beach : University Cancer Institute, Site #149

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Boynton Beach : Hematology And Medical Oncology Of Southern Palm Beach County

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Fort Myers : Florida Cancer Specialists, Site #180

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Hialeah : Palm Springs Research Institute

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Jacksonville : Baptist Cancer Institute

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

View More »

Jacksonville : University Of Florida

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Lakeland : Watson Clinic

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Miami : University of Miami

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

New Port Richey : Florida Cancer Specialists

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Orlando : Cancer Centers of Florida

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

St. Petersburg : Florida Cancer Specialists, Site #179

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Tavares : Lake County Oncology and Hematology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Titusville : Space Coast Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Atlanta : Emory University, Site #058

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Atlanta : Emory University

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Marietta : Northwest Georgia Oncology Centers, PC

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Sandy Springs : Georgia Cancer Specialist

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Honolulu : OnCare

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Honolulu : Straub Clinical & Hospital

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Chicago : Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Chicago : University of Chicago, Site #001

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Evergreen Park : Mahafzah Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Maywood : Loyola University Chicago, Site #054

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Maywood : Loyola University Medical Center, Cardinal Bernardin Cancer Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

View More »

Niles : Orchard Health Care Research

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Normal : Mid-Illinois Hem/Onc Asoc

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

North Chicago : North Chicago VA Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Springfield : Southern Illinois School of Medicine

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Anderson : Saint John's Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Beech Grove : Indiana Blood and Marrow Institute SC

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Beech Grove : Indiana Blood and Marrow Transplantation, LLC

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Indianapolis : Indiana University Riley Hospital for Children

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Indianapolis : Franciscan St. Francis Health, Site #138

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

View More »

Indianapolis : Indiana Blood and Marrow Transplantation

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Indianapolis : Investigative Clinical Research of Indiana

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

New Albany : Cancer Care Center, Inc. PC

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Iowa City : University of Iowa Hospitals and Clinics, Site #050

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Mason City : N. Iowa Mercy Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Hutchinson : Hutchinson Clinic

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Topeka : Cotton O'Neil Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Wichita : US Oncology - Cancer Center of Kansas, Site #168

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Wichita : Cancer Center of Kansas

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Lexington : Central Baptist Hospital

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Shreveport : Willis-Knighton Cancer System

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Baltimore : St. Agnes Hospital SC

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Baltimore : University of Maryland, Greenebaum Cancer Center, Site #040

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Baltimore : Greater Baltimore Medical Center, Site #140

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Columbia : Maryland Oncology Hematology Pa

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Boston : Dana Farber Cancer Institute, Site #008

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Boston : Massachusetts General Hospital, Site #047

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Boston : Boston VA Healthcare System

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Quincy : Commonwealth Hematology-Oncology, P.C.

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Worcester : University of Massachusetts Memorial Medical Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Ann Arbor : University of Michigan Medical Center, Site #011

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Kalamazoo : West Michigan Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Lansing : Michigan State University

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Minneapolis : University of Minnesota

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Rochester : Mayo Clinic, Site #044

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Kansas City : Saint Luke's Hospital, Site #162

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Springfield : Mercy Clinic - Cancer & Hematology, Site #151

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Springfield : St John's Clinic for Cancer and Hematology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Billings : Billings Clinic

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Lincoln : Nebraska Hematology-Oncology, P.C., Site # 133

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Omaha : Omaha VAMC

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Las Vegas : US Oncology - Comprehensive Cancer Center of Nevada, Site #169

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Portsmouth : Portsmouth Regional Hospital

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Hackensack : John Theurer Cancer Center, Site #128

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Hackensack : Hackensack University Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Morristown : Hematology-Oncology Associates of Northern NJ, PA

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Vineland : Southern Oncology Hematology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Albuquerque : University of New Mexico Cancer Center, Site #166

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bronx : Montefiore Medical Center / AECOM

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Johnson City : Broome Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Mineola : Winthrop University Hospital, Site #153

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

New York : Memorial Sloan Kettering Cancer Center

A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene

New York : Weill Cornell Medical College, Site #006

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

View More »

New York : Memorial Sloan-Kettering Cancer Center, Site #078

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

New York : St. Lukes Roosevelt Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

New York : Advanced Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Stony Brook : Stony Brook University Hospital

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Valhalla : New York Medical College, Site #146

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Cary : Waverly Hematology Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Charlotte : Levine Children's Hospital

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Durham : Duke University Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Gastonia : Gaston Hematology Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Greenville : East Carolina University

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

View More »

Raleigh : Rex Cancer Center - Wakefield

Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Raleigh : Rex Cancer Center

Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Akron : Akron General Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Cincinnati : Cincinnati Children's Hospital Medical Center Cincinnati Children's Hosp

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Cleveland : Cleveland Clinic

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Middletown : Signal Point Clinical Research Center, Site #139

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Middletown : Signal Point Clinical Research Center, LLC

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

View More »

Newark : Medical Center of Newark

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Oklahoma City : University of Oklahoma, Site #028

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Tulsa : Cancer Care Associates

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Portland : Oregon Health & Science University, Site #048

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Portland : Oregon Health & Science University

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Salem : Hematology/Oncology Salem LLP

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Gettysburg : Gettysburg Cancer Center, Site #160

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Kingston : Medical Oncology Associates of Wyoming Valley, PC

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Lancaster : Lancaster General Health

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Norristown : Luitpold Pharmaceuticals, Inc.

Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

Philadelphia : Children's Hospital of Philadelphia Pediatric Oncology Clinic

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

View More »

Pittsburgh : Western Pennsylvania Hospital, Site #159

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Pittsburgh : The Western Pennsylvania Hospital

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Pittsburgh : Veterans Research Foundation of Pittsburgh

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Wilkes-Barre : Geisinger Health System

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

York : Cancer Care Association Of York

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Cranston : Hematology and Oncology Associates of RI

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Charleston : Medical University of South Carolina, Site #148

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Charleston : Charleston Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Sumter : Carolina Hematology Oncology, Site #143

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Sioux Falls : Avera Research Institute

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Watertown : Prairie Lakes Healthcare System, Inc

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Knoxville : Tennessee Cancer Specialists

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Nashville : Sarah Cannon Research Institute

A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene

Nashville : Sarah Cannon Research Institute, Site #076

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Amarillo : Texas Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Arlington : Texas Oncology - Arlington South

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Austin : US Oncology - Texas Oncology Austin, Site #172

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Austin : Texas Oncology-Austin North

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Beaumont : Julie & Ben Rogers Cancer Institute

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

View More »

Dallas : US Oncology - Texas Oncology Dallas, Site #171

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Dallas : Texas Oncology-Dallas Presbyterian Hospital

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Dallas : Texas Oncology-Methodist Charlton Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Dallas : Texas Oncology-Medical City Dallas

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Houston : University of Texas M.D. Anderson Cancer Center

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Houston : The University of Texas MD Anderson Cancer Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Houston : MD Anderson Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Houston : Michael DeBakey VA Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Lewisville : Texas Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

McAllen : Texas Oncology-McAllen South Second

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Mesquite : Texas Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Midland : US Oncology - Texas Oncology Midland, Site #173

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Midland : Texas Oncology-Midland Allison Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Odessa : Texas Oncology-Odessa West Texas Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Paris : Texas Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Plano : North Texas Regional Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

San Antonio : US Oncology - Cancer Care Center of South Texas, Site #170

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

San Antonio : Cancer Care Centers of South Texas

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Waco : Texas Oncology

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Salt Lake City : Huntsman Cancer Institute, Site #043

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Fredericksburg : Hematology Oncology Associates of Fredricksburg

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Newport News : Peninsula Cancer Institute

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Roanoke : Blue Ridge Cancer Care

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Seattle : Seattle Cancer Care Alliance, Site #100

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Spokane : Providence Cancer Center at Sacred Heart Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Vancouver : US Oncology - Northwest Cancer Specialists, Site #174

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Wenatchee : Wenatchee Valley Medical Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Yakima : Yakima Valley Memorial Hospital/North Star Lodge

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Morgantown : West Virginia University - Clinical Trials Research Unit

AP24534 - A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adults with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

View More »

Martinsburg : City Hospital - West Virginia University Hospital East

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Morgantown : West Virginia University, Site #154

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Wheeling : Wheeling Hospital

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Wausau : Aspirus Regional Cancer Center

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Buenos aires : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Buenos Aires : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Rio Negro : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Adelaide : Royal Adelaide Hospital, Site #951

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

East Melbourne : The Peter MacCallum Cancer Center, Site #950

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Garran : Canberra Hospital, Site #971

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Melbourne : Box Hill Hospital, Site #940

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Perth : Royal Perth Hospital, Site #972

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bruxelles : Clinique Universitaire de Saint-Luc, Department of Haematology, Site #508

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Leuven : UZ Gasthuisberg - Department of Hematology, Site #700

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Barretos : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Curitiba : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Goiania : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Porto Alegre : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Porto Alegre : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

View More »

Salvador : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Sao Paulo : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

São Paulo : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Hamilton : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Montreal : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Montreal : Jewish General Hospital, Site #129

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Québec : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Saskatoon : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

View More »

Toronto : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Toronto : University Health Network, Princess Margaret Hospital, Site #083

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Vancouver : Leukemia BMT program of BC, Vancouver General Hospital, Hematology Research and Clinical Trials Unit

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

Shanghai : Shanghai Jiaotong University School of Medicine Ruijin Hospital

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Hradec Kralove : FN Hradec Kralove, Site #517

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Helsinki : Helsinki University Central Hospital, Site #542

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bordeaux : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Bordeaux : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Bordeaux : Institut Bergonie, Site #772

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Le Chesnay Cedex : Centre Hospitalier de Versailles, Site #958

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Lille cedex : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

View More »

Lille Cedex : Hospital Claude Huriez, Site #952

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Nancy Cedex : CHU de Brabois, Site #953

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Paris : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Paris : Hospital Saint Antoine, Site #518

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Paris Cedex 19 : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Pierre Benite : Centre Hospitalier Lyon Sud, Site #956

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Pierre Benite : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Pierre-Benite Cédex : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Poitiers : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Poitiers : CHU de Poitiers, Site #954

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Vandoeuvre les Nancy : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Aachen : Universitätsklinikum Aachen, AÖR, Site #513

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Amberg : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Aschaffenburg : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Baden-Baden : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Bamberg : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

View More »

Berlin : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Berlin : Charite - Universitatsmedizin Berlin, Site #701

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bottrop : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Dresden : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Dresden : Universitatsklinikum Carl Gustav Carus an der TU Dresden, Site #526

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Essen : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Frankfurt am Main : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Frankurt am Main : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Freiburg : Universitatsklinikum Freiburg, Site #527

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Hamburg : Universitatsklinikum Hamburg-Eppendorf, Site #524

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Hof : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Jena : Universitatsklinikum Jena, Site #946

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Koblenz : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Koln : Universitatsklinikum Koln-AOR, Site #525

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Köln : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Landshut : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Leipzig : Novartis Investigative Site

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

Mannheim : Universitat Heidelberg, CML - Studienzentrale III. Medizinische Klinik, Site #947

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Mülheim a. d. Ruhr : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Munchen : Klinikum rechts der Isar, Site #949

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Offenbach : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Potsdam : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Rostock : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Rötha : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Singen : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Soest : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Ulm : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Weiden : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Hong Kong : Queen Mary Hospital, Site #973

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Jerusalem : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Ramat Gan : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Bari : Unita Operativa di Ematologia con Trapianto, Site #529

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bologna : Istituto di Ematologia "L. & A. Seragnoli", Site #959

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Catania : A.O. Universitaria Policlinico Vittorio Emanuele di Catania, Site #530

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Genova : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Genova : Clinica Ematologica, Site #528

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

View More »

Milan : Ospedale Niguarda Ca' Granda di Milano, Site #531

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Milan : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Milano : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Modena : S.C. Ematologia, Site #960

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Monza : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Monza : San Gerardo Hospital, Site #961

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Napoli : Universita Federico II, Site #510

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Orbassano : SCDU Medicina Interna II - Indirizzo Ematologico, Site #785

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Padova : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Roma : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Nagoya : Updated

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Tokyo : Updated

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Seocho-gu : The Catholic University of Korea, Site #938

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Seoul : Seoul St. Mary's Hospital

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib

Amsterdam : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Amsterdam : VU Medical Centre - Department Haematology, Site #948

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Hoofddorp : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Rotterdam : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Christchurch : Christchurch Hospital, Site #922

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Grafton : Auckland City Hospital, Site #921

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Hamilton : Waikato Hospital, Site #977

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Takapuna : North Shore Hospital, Site #976

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bayamon : Puerto Rico Hematology Oncology Group

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Arkhangelsk : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Ekaterinburg : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Irkutsk : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Moscow : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Nizhnii Novgorod : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

View More »

Perm : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Rostov-on-Don : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Ryazan : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Saint-Petersburg : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

St Petersburg : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

St Petersburg : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

St Petersburg : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Tula : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Singapore : Singapore General Hospital, Site #939

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Bratislava : Narodny onkologicky ustav, Site #532

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Martin : Univerzitna nemocnica Martin, Site #533

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

A Coruna : Complejo Hospitalario Universitario A Coruna, Hospital "Teresa Herrera," Site #554

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Alicante : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Badalona : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Badalona : Hospital Universitari Germans Trias i Pujol, Site #512

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Barcelona : Hospital Clinic, Site #963

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

View More »

Girona : Institut Catala d' Oncologia de Girona, S. de Hematologia Clinica, Site #734

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Islas Baleares : Hospital Universitari Son Espases, Site #553

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Madrid : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Madrid : Hospital Gregorio Maranon, Site #536

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Madrid : Hospital Universitario 12 de Octubre, Site #537

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Madrid : H.U. Ramon y Cajal, Site #538

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Madrid : Hospital La Paz, Site #966

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Oviedo : Hospital Universitario Central de Asturias, Site #535

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Salamanca : Hospital Universitario de Salamanca, Site #965

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Santiago de Compostela-A Coruña : Local Institution

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Sevilla : Novartis Investigative Site

A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Valencia : Hospital Clinico Universitario de Valencia, Site #964

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Lund : Skane University Hospital, Site #944

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Stockholm : Karolinska University Hospital Solna, Site #763

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Stockholm : Karolinska University Hospital Huddinge, Site #534

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Uppsala : Uppsala University Hospital, Site #945

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Aarau : Kantonsspital Aarau, Site #541

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Lin-Ko : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Niaosong Township : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Taiching : China Medical University Hospital, Site #978

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Taipei : National Taiwan University Hospital, Site #979

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Taipei : Novartis Investigative Site

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Bangkok : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Birmingham : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Bristol : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Glasgow : University of Glasgow, Site #797

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Glasgow : Novartis Investigative Site

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Leeds : St. James University Hospital, Site #540

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

View More »

Liverpool : Royal Liverpool University Hospital, Site #969

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

London : Hammersmith Hospital, Site #967

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Manchester : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Newcastle : Newcastle University, Site #970

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Nottingham : Nottingham University Hospitals NHS Trust, Site #968

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Oxford : Oxford University Hospitals NHS Trust, Site #543

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Sutton : Novartis Investigative Site

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)